Literature DB >> 14689348

Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis.

Michael D Edstein1, David A Kocisko, Douglas S Walsh, Chirapa Eamsila, Bruce G Charles, Karl H Rieckmann.   

Abstract

We measured plasma tafenoquine concentrations in Thai soldiers given a monthly regimen of tafenoquine to determine whether these concentrations adequately suppressed malarial infections on the Thai-Cambodian border. After receiving a treatment course of artesunate and doxycycline, 104 male soldiers were administered a loading dose of tafenoquine (400 mg daily for 3 days), followed by tafenoquine monthly (400 mg every 4 weeks) for 5 months. Consecutive monthly mean (+/- standard deviation) trough plasma tafenoquine concentrations were 223+/-41, 127+/-29, 157+/-51, 120+/-24, and 88+/-20 ng/mL. Only 1 soldier developed malaria during the study. At the time of malaria diagnosis, his plasma tafenoquine concentration was 40 ng/mL, which was approximately 3-fold lower than the trough concentrations of the other soldiers. Although low tafenoquine concentrations appear to be uncommon, additional investigations are needed to determine the relationship between plasma tafenoquine concentrations and suppression of malaria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14689348     DOI: 10.1086/379718

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti.

Authors:  Bruno Pradines; Modeste Mabika Mamfoumbi; Adama Tall; Cheikh Sokhna; Jean-Louis Koeck; Thierry Fusai; Joel Mosnier; Eric Czarnecki; André Spiegel; Jean-François Trape; Maryvonne Kombila; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Tafenoquine and G6PD: a primer for clinicians.

Authors:  Cindy S Chu; David O Freedman
Journal:  J Travel Med       Date:  2019-06-01       Impact factor: 8.490

3.  Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?

Authors:  Dana G Mordue; Gary P Wormser
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

4.  Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries.

Authors:  Geoffrey S Dow; Jun Liu; Gina Lin; Brian Hetzell; Sarah Thieling; William F McCarthy; Douglas Tang; Bryan Smith
Journal:  Malar J       Date:  2015-11-26       Impact factor: 2.979

Review 5.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Senaka Rajapakse; Chaturaka Rodrigo; Sumadhya Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2015-04-29

6.  A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.

Authors:  Geoffrey S Dow; William F McCarthy; Mark Reid; Bryan Smith; Douglas Tang; G Dennis Shanks
Journal:  Malar J       Date:  2014-02-06       Impact factor: 2.979

Review 7.  The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).

Authors:  Geoffrey Dow; Bryan Smith
Journal:  Malar J       Date:  2017-05-19       Impact factor: 2.979

8.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2020-09-06

9.  Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis.

Authors:  Alexander P Gorka; Lauren M Jacobs; Paul D Roepe
Journal:  Malar J       Date:  2013-09-18       Impact factor: 2.979

Review 10.  Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Authors:  Yehenew A Ebstie; Solomon M Abay; Wondmagegn T Tadesse; Dawit A Ejigu
Journal:  Drug Des Devel Ther       Date:  2016-07-26       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.